Premium
Microfluidic Synthesis of Gd‐Based Nanoparticles for Fast and Ultralong MRI Signals in the Solid Tumor
Author(s) -
Li Xuanyu,
Feng Qiang,
Jiang Xingyu
Publication year - 2019
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201900672
Subject(s) - magnetic resonance imaging , plga , nanoparticle , materials science , biomedical engineering , drug delivery , solid tumor , microfluidics , contrast (vision) , nuclear magnetic resonance , nanotechnology , cancer , medicine , radiology , computer science , physics , artificial intelligence
Abstract Clinically used magnetic resonance imaging contrast agents (MRI CAs) for solid tumors suffer from short life spans and low accumulation at the tumor for their low molecular weights. A good solution is to incorporate these MRI CAs into nanoparticles. Food and Drug Administration‐approved compounds, poly(lactic‐ co ‐glycolic acid) (PLGA) and lipids, are chosen to assemble these nanoparticles. PLGA/lipid hybrid nanoparticles are assembled in microfluidic channels with a suitable size distribution for imaging tumors. These nanoparticles achieve clearly enhanced MRI contrast at the tumor at 0.5 h postinjection. The enhanced MRI contrast is sustained for 16 h. They can margin the tumor with as good an enhanced MRI contrast as clinical MRI CAs (which visualize the whole tumor) of the solid tumor with much less Gd. They are particularly useful for monitoring the solid tumor after therapy within a day and without repeated administration as clinical MRI CAs.